Companies
PBS Biotech
sells single-use Vertical-Wheel bioreactors (including a 15L system for cell-therapy scale-up) using a low-shear vertical impeller design documented in peer-reviewed research to predict maximum achievable cell density before oxygen-transfer becomes limiting for iPSC aggregate cultures.
- Country
- United States
Commercial
Vertical-Wheel single-use bioreactors incl. 15L cell-therapy scale-up system; low-shear mixing
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| upstream-bioreactors | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $58.68M total funding (latest $17M in Jan 2025) | prnewswire.com |
| Capacity | expanding capacity to support over $100M in annual revenue as of 2025 | prnewswire.com |
| Certification | ISO 9001:2015 certified; products meet USP Class VI and/or ISO 10993 standards | pbsbiotech.com |
| Regulatory approval | products manufactured to meet cGMP standards, with software options for 21 CFR Part 11 compliance | pbsbiotech.com |
| Production site | 63,800 sq. ft. facility in Camarillo, California, USA | pbsbiotech.com |
| Headcount | approximately 104-105 employees as of 2026 | getlatka.com |
| Revenue | $31.6M in 2025 medium confidence | getlatka.com |
Independent sources: getlatka.com · prnewswire.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| High-cell-density culture systems | upstream-bioreactors | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.